When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SBBP - Strongbridge Biopharma's Recorlev Phase 3 Topline Data Due September 2020 Is A Major Value Inflection Point
Strongbridge Biopharma plc
Stonebridge Biopharma plc (SBBP) is nearing its transformational value inflection point with the expected release of Recorlev's Phase 3 topline data for Cushing's disease due next month (September 2020). If Recorlev's Phase 3 topline data is good enough, SBBP will file a NDA in Q1 2021 with hopefully FDA approval 10 months later. This is Recorlev's second Phase 3 trial. If approved in December 2021, there would then be 2 roadmaps to material shareholder valuation gains from SBBP's Recorlev asset. Valuation gains could come from the sale of Recorlev to a Big Pharma